Efpeglenatide

Efpeglenatide is a long-acting GLP-1 receptor agonist developed by Hanmi Pharmaceutical of South Korea. The molecule is based on the exenatide GLP-1 agonist conjugated through a flexible linker to a non-glycosylated human IgG4 Fc fragment. The Fc conjugation extends plasma half-life and enables once-weekly subcutaneous dosing. Phase 3 trials in the AMPLITUDE program established efficacy in type 2 diabetes and cardiovascular safety. The compound is not FDA-approved.

The molecule was originally developed using Hanmi's proprietary LAPSCOVERY platform, which links peptide payloads to Fc fragments to extend pharmacokinetics. The same platform produced lixisenatide-based and other peptide conjugates in Hanmi's pipeline. Development partnership with Sanofi began in 2015 and included the Phase 3 AMPLITUDE program. Sanofi returned the rights to Hanmi after the program completed, citing strategic pipeline decisions. The compound has since languished in regulatory limbo.

The development trajectory illustrates a recurring tension in GLP-1 pharmaceutical development. Efficacy and cardiovascular safety in trials does not guarantee marketing authorization. Commercial considerations, competitor pipeline positioning (notably the entry of Semaglutide once-weekly and Tirzepatide as a dual agonist), and regulatory submission strategy all influence which Phase 3 successes become approved products.

The Human Evidence

The AMPLITUDE program comprised multiple Phase 3 trials in type 2 diabetes. Key results:

AMPLITUDE-O (Gerstein et al., NEJM 2021). Cardiovascular outcomes trial in 4,076 adults with type 2 diabetes and history of cardiovascular disease or kidney disease. Efpeglenatide at 4 mg or 6 mg weekly reduced the primary three-point MACE composite (cardiovascular death, non-fatal MI, non-fatal stroke) by 27 percent versus placebo (hazard ratio 0.73, p < 0.001 for non-inferiority and p = 0.007 for superiority). The trial established the compound as the first exenatide-derived GLP-1 agonist to demonstrate Phase 3 cardiovascular outcome benefit. Secondary endpoints showed reductions in kidney disease progression.

AMPLITUDE-M (Frias et al., 2022). Efpeglenatide monotherapy in 401 adults with type 2 diabetes inadequately controlled by diet and exercise. Dose-dependent HbA1c reductions of 1.1 to 1.6 percent and weight reductions of 2.0 to 3.4 kg over 30 weeks.

AMPLITUDE-D (Pratley et al., 2022). Head-to-head trial of efpeglenatide vs dulaglutide in 1,092 adults. The two compounds produced broadly comparable glucose-lowering and weight-loss effects, with efpeglenatide non-inferior on the primary endpoint.

The AMPLITUDE data put efpeglenatide solidly in Tier 1 evidence territory (Phase 3 complete, cardiovascular safety established). The absence of FDA approval is a commercial outcome rather than an efficacy or safety failure.

Regulatory and Legal Status

FDA. Not approved. No marketing authorization has been submitted by Hanmi or any partner as of May 2026.

EMA. Not approved.

Compounding. Not on the FDA bulk drug substances list. The molecule is patent-protected and cannot legally be compounded by US 503A or 503B pharmacies under current rules.

WADA. GLP-1 receptor agonists are not on the 2026 Prohibited List as a class.

Research-chemical availability. Some vendors offer efpeglenatide-labeled product. Identity verification is the buyer's responsibility, and equivalence to clinical-trial-grade material cannot be assumed.

Efpeglenatide is a peptide-Fc fusion molecule based on exenatide, the GLP-1 receptor agonist derived from Gila monster Heloderma suspectum venom. The active GLP-1 agonist portion binds the GLP-1 receptor on pancreatic beta cells, hypothalamic neurons, the area postrema, and the vagus nerve.

Direct receptor effects. GLP-1 receptor activation triggers glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release from alpha cells, slows gastric emptying, and reduces appetite through central mechanisms. The glucose-dependence of insulin secretion is the basis for the favorable hypoglycemia risk profile compared with sulfonylureas.

Fc fragment conjugation. The non-glycosylated human IgG4 Fc fragment extends plasma half-life through neonatal Fc receptor (FcRn)-mediated recycling. The mechanism is the same biology that gives therapeutic antibodies their long half-lives. The flexible linker between exenatide and Fc preserves GLP-1 receptor binding while enabling the extended pharmacokinetics. Half-life is approximately 5 to 6 days after subcutaneous administration, supporting once-weekly dosing.

Pharmacokinetics. Tmax approximately 3 to 5 days after subcutaneous injection. Steady state reached after 4 to 5 weekly doses. Clearance is primarily through proteolytic degradation; renal clearance is minimal because of the Fc-mediated FcRn recycling. The Fc-based platform produces somewhat different pharmacokinetic behavior compared with fatty-acid-modified agonists like semaglutide (albumin binding) or dulaglutide (also Fc-fused).

The receptor pharmacology is GLP-1-monoagonist. Efpeglenatide does not engage GIP receptors (Tirzepatide, dual agonist) or glucagon receptors (Retatrutide, triple agonist). This places it in the same broad pharmacological category as Semaglutide, Liraglutide, Dulaglutide, Lixisenatide, Albiglutide, and Exenatide.

Trial-documented effects in type 2 diabetes populations:

• HbA1c reduction of 1.1 to 1.6 percent (dose-dependent) over 30 to 56 weeks
• Body weight reduction of 2 to 6 kg over 56 weeks
• 27 percent reduction in three-point MACE in AMPLITUDE-O
• Reduction in kidney disease progression markers in AMPLITUDE-O
• Improvement in fasting plasma glucose
• Modest reductions in systolic blood pressure (1 to 3 mmHg)

No Phase 3 trial has tested efpeglenatide in non-diabetic obese populations specifically for weight loss, unlike the Semaglutide STEP program. The weight-loss data is a secondary endpoint from type 2 diabetes trials and may underestimate the effect that would be seen in a dedicated obesity program.

The AMPLITUDE-O trial used three weekly subcutaneous doses: 2 mg, 4 mg, and 6 mg. The 4 mg and 6 mg doses produced cardiovascular outcome benefit; the 2 mg arm was discontinued for futility on the primary efficacy endpoint.

The AMPLITUDE-M monotherapy trial used 2 mg, 4 mg, and 6 mg weekly with dose-dependent HbA1c and weight effects. Titration from a starting dose with subsequent dose escalation over 4 to 6 weeks improved gastrointestinal tolerability.

No FDA-approved dosing protocol exists because the compound is not approved. The Phase 3 doses represent the most reliable reference for what the trial program tested in monitored settings.

Research-chemical use outside investigational settings sits outside the medical regulatory framework. Identity and purity of vendor product cannot be assumed equivalent to clinical-trial-grade material.

Phase 3 adverse-event profile aligns with the GLP-1 class:

• Nausea (20 to 35 percent, dose-dependent)
• Vomiting (8 to 15 percent)
• Diarrhea (10 to 18 percent)
• Constipation (5 to 8 percent)
• Injection site reactions (3 to 7 percent)
• Decreased appetite (5 to 10 percent)
• Increased heart rate (1 to 3 bpm at maintenance dose)
• Mild ALT elevations in a subset of participants

The discontinuation rate due to gastrointestinal adverse events was approximately 5 to 8 percent across dose ranges in AMPLITUDE-M, lower than rates seen with dual and triple agonists at equivalent efficacy doses.

Class-effect safety considerations for GLP-1 receptor agonists include the boxed warning on rodent C-cell tumor findings (relevance to humans uncertain), risk of acute pancreatitis (reported in post-marketing data for the GLP-1 class), gallbladder events (cholelithiasis incidence higher in GLP-1 class), and effects on diabetic retinopathy progression in subsets of patients. These class-level findings apply to efpeglenatide based on mechanistic similarity, though efpeglenatide-specific incidence data is limited to the AMPLITUDE program.

Long-term safety beyond the AMPLITUDE follow-up window has not been characterized in non-trial populations.

Within the GLP-1 receptor agonist class, efpeglenatide sits at a similar pharmacological position to Dulaglutide (also Fc-fused once-weekly), Semaglutide (fatty-acid-modified once-weekly), and Albiglutide (HSA-fused once-weekly, withdrawn). Mechanistic distinctions among these compounds are modest. Commercial trajectory and trial portfolio drive clinical adoption more than receptor pharmacology differences.

Combination protocols with Cagrilintide (amylin analog) have been studied for other GLP-1 agonists but not for efpeglenatide specifically. The investigational CagriSema combination (semaglutide plus cagrilintide) and trial-stage tri-agonists like Retatrutide represent the next-generation pharmacology that efpeglenatide development would have to compete against if revived.

For users evaluating GLP-1 options, the practical comparison is between approved products with established safety, supply chain, and insurance coverage (semaglutide, tirzepatide, liraglutide, dulaglutide) and investigational or research-chemical alternatives like efpeglenatide. The latter category offers no regulatory or quality advantage and adds verification risk.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.